Peptilogics

Peptilogics is a clinical-stage biotechnology company focused on transforming the discovery and development of novel peptide therapeutics. The company leverages the untapped potential of peptide biology combined with the power of machine learning to scale its drug design approach. Peptilogics aims to usher in the next generation of peptide therapeutics through precision engineering and design. Its lead therapeutic, PLG0206, is a novel, broad-spectrum anti-infective currently under clinical investigation for the treatment of prosthetic joint infection, a condition with significant unmet medical needs. The company primarily serves patients with serious and life-threatening diseases, operating within the biotechnology and pharmaceutical markets. Peptilogics generates revenue through the development and potential commercialization of its peptide-based drugs.

Keywords: peptide therapeutics, machine learning, drug design, clinical-stage, biotechnology, anti-infective, prosthetic joint infection, precision engineering, peptide biology, pharmaceutical.